Annual report pursuant to Section 13 and 15(d)

Iloperidone Sublicense to Novartis Pharma AG

v2.4.1.9
Iloperidone Sublicense to Novartis Pharma AG
12 Months Ended
Dec. 31, 2014
Iloperidone Sublicense to Novartis Pharma AG [Abstract]  
Iloperidone Sublicense to Novartis Pharma AG [Text Block]
5. Iloperidone Sublicense to Novartis Pharma AG
 
We are party to an agreement with Novartis, which, as amended, granted Novartis a worldwide sublicense to iloperidone (Fanapt®) in exchange for tiered royalties on net sales ranging from 8% to 10% and assumption of responsibility for all clinical development, registration, manufacturing and marketing of the product. Novartis had the right to commercialize Fanapt in the United States and Canada. In December 2014, Novartis transferred all rights to commercialize Fanapt in the United States and Canada to Vanda Pharmaceuticals, Inc. Our rights under the agreements have not changed. Pursuant to agreements entered into during 2011, we sold substantially all of our remaining future royalties on the sales of Fanapt® to Deerfield, and accordingly the future royalty payments owed to us by Novartis will continue to be transmitted to Deerfield upon receipt from Novartis per the terms of the agreement with Deerfield. See Note 8, “Royalty Liability” for further discussion of our royalty liabilities.